Trial
NCT02323906
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Carcinoma, Hepatocellular
Intervention
CC-122
Why stopped
Slow enrollment and business decision. No safety concerns were identified for the study drugs.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-20